Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest immunotherapies Stories

2014-04-02 23:32:49

Presentation details three separate tuberculosis immunotherapies developed by Immunitor in collaboration with academic institutions and private companies in Mongolia, China, Thailand, Ukraine, UK, USA and Canada. Data presented support the Immunitor strategy to target inflammation as the main cause of TB and development of immunomodulators and therapeutic vaccines which demonstrate ability to rapidly clear TB, including MDR-TB and TB with HIV. Vancouver, BC, Canada (PRWEB) April 02, 2014...

2014-03-20 23:31:05

MedVax Technologies, Inc., a biopharmaceutical company developing and commercializing cancer vaccine immunotherapies, announced today that Robert Brooks, Chief Executive Officer, will be presenting a company overview at the 6th Annual Biotech Showcase investor and partnering conference. Miami, FL (PRWEB) March 20, 2014 MedVax Technologies, Inc., a biopharmaceutical company developing and commercializing cancer vaccine immunotherapies, announced today that Robert Brooks, Chief Executive...

2014-03-19 20:21:22

-- Collaboration Focused on Cancer Immunotherapies for Pets -- KANSAS CITY, Kan., and PRINCETON, N.J., March 19, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, and Advaxis, Inc. (NASDAQ: ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced a global...

2014-03-06 13:13:25

Ludwig researchers show that infecting just 1 tumor with a virus could boost the systemic effectiveness of cancer immunotherapy A Ludwig Cancer Research study suggests that the clinical efficacy of checkpoint blockade, a powerful new strategy to harness the immune response to treat cancers, might be dramatically improved if combined with oncolytic virotherapy, an investigational intervention that employs viruses to destroy tumors. Published today in the journal Science Translational...

2014-02-11 08:33:33

AMSTERDAM, February 11, 2014 /PRNewswire/ -- - SynCo's live microbial track record, GMP scale-up and commercial manufacturing capabilities will facilitate the advancement of Advaxis' ADXS-HPV program - SynCo Bio Partners B.V. [http://www.syncobiopartners.com ], a leading services provider for GMP manufacturing of live microbial vaccines and biotherapeutics today announces that they have entered into a long term manufacturing collaboration with Advaxis, Inc....

2014-01-28 08:30:47

DURHAM, N.C., Jan. 28, 2014 /PRNewswire/ -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis(TM) technology platform, today announced that the company will present a trial-in-progress update on the company's ongoing pivotal phase 3 clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC). The...

2014-01-23 04:21:21

Inovio develops DNA-based immune booster (IL-33) that enhances T-cell responses and generates effective CD8 mediated tumor regression BLUE BELL, Pa., Jan. 23, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today unveiled that the company has developed a new DNA-based cytokine immune activator, interleukin -33 (IL-33), that in combination with optimized DNA vaccines delivered by electroporation increased the potency and efficacy of the therapeutic response to the...

2014-01-13 16:25:48

Juno CEO Hans Bishop to Address JP Morgan's 32nd Annual Healthcare Conference SEATTLE, Jan. 13, 2014 /PRNewswire-USNewswire/ -- Juno Therapeutics, a new biotechnology company focused on bringing forward novel immunotherapies for cancer, announced today an expanded Series A including Bezos Expeditions, the personal investment company of Jeff Bezos, and leading venture capital firm Venrock. The total Series A will exceed $145M. (Logo:...

2013-11-20 08:30:05

DURHAM, N.C., Nov. 20, 2013 /PRNewswire/ -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis(TM) technology platform, today announced that on November 4, 2013, the Company increased the size of its previously announced Series E financing by $17.5 million, bringing the total amount of committed funds from $42.5 million to $60...

2013-11-13 04:23:00

TUEBINGEN, Germany, and BASEL, Switzerland, November 13, 2013 /PRNewswire/ -- Collaboration spans the discovery, development and commercialisation of cancer vaccines and other cancer immunotherapies in gastric, lung and prostate cancer immatics biotechnologies GmbH and Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced a strategic research and development collaboration covering multiple cancer vaccines and immunotherapeutics. The agreement will focus on...